Impact of Ocrelizumab Vs. Interferon Beta-1a In Delaying The Deterioration Of Patients' Daily Functions and Associated Costs In Relapsing-Remitting Multiple Sclerosis

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1933
https://www.valueinhealthjournal.com/article/S1098-3015(17)32267-2/fulltext
Title : Impact of Ocrelizumab Vs. Interferon Beta-1a In Delaying The Deterioration Of Patients' Daily Functions and Associated Costs In Relapsing-Remitting Multiple Sclerosis
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32267-2&doi=10.1016/j.jval.2017.08.1933
First page : A721
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1764
Categories :
Tags :
Regions :
ViH Article Tags :